Regentis Biomaterials GelrinC Demonstrates True Hyaline Cartilage Regeneration Two Years Post-Treatment In Long-Term Clinical Trial Data

2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint function

This rare outcome in cartilage repair suggests true biological cartilage regeneration, not merely defect filling

Unlike traditional scaffolds, GelrinC limits fibrotic tissue overgrowth, supporting smoother joint motion and preserving natural biomechanics

HERZLIYA, IL / ACCESS Newswire / January 20, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced new long-term imaging data from its successfully completed European clinical trial of GelrinC®, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage.

The data, published in the peer-reviewed journal Cartilage, are based on an advanced MRI analysis of patients treated with GelrinC® for focal cartilage defects in the knee. MRI findings revealed progressive improvement in tissue organization over time, indicating continued maturation of the regenerated cartilage well beyond implantation. By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilage, which is widely regarded as the gold standard for long-term joint durability and function. This degree of structural organization suggests that GelrinC® supports the formation of cartilage with true biological quality, rather than fibrotic or scar-like repair tissue.

The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings.